The latest news, trends, analysis, interviews and podcasts from the global food and beverage industry
Dutch food-tech company The Protein Brewery has today (29 June 2026) announced an €18 million extension of its Series B funding round, led by ABN AMRO Sustainable Impact Fund.
The company – a producer of mycelium-based ingredients, headquartered in Breda, the Netherlands – expanded the round beyond its initial target thanks to ‘strong investor demand’. In September 2025, it successfully closed a €30 million Series B funding round, with the latest extension bringing its total funding raised to date to more than €70 million.
Joined by existing investors Invest-NL, Novo Holdings, Madeli and the Brabant Development Agency, the round will support The Protein Brewery’s continued growth. Particularly, it will help increase production capacity of its flagship Fermotein ingredient and expand commercially across Europe.
The funding news comes just a couple of weeks after The Protein Brewery celebrated a major milestone in the approval of Fermotein in the European Union: the first whole-food novel mycelium ingredient to be approved for sale on the market under the EU Novel Food Regulation.
Fermotein is a ‘mycoprotein’ ingredient made from the fungus Rhizomucor pusillus, designed to deliver clean-label and vegan-friendly nutrition across a wide range of food and beverage applications.
With its latest funding raise, The Protein Brewery aims to expand production capacity to more than 2,000 MT through scaling operations at its facility in Mijkenbroek.
After summer 2026, the company will focus on driving sales into Europe with a primary focus on active nutrition, including ready-to-mix powders and bars, and other functional foods and beverages.
Investment will also support the advancement of clinical and scientific research into the ‘longevity-promoting’ benefits of Fermotein, as well as pursuing further regulatory approvals in new markets including Canada, Australia, New Zealand and India.
Thijs Bosch, CEO of The Protein Brewery, said: “Building a completely new ingredient category takes patience and investment in the right activities, at the right time. With this additional funding, we move from proving that whole-food mycelium is a desirable ingredient to delivering it at the scale that brands and manufacturers need.”
Due to Fermotein’s nutritional profile – containing approximately 50% protein with all essential amino acids, and 30% dietary fibre – the company believes it is ideally positioned to meet demand for functional foods targeting longevity, gut health, metabolic health (including GLP-1 support) and muscle maintenance.
The Protein Brewery has already sold out its 2026 capacity to customers in the US, and is working with initial customers in active nutrition in the EU and UK.
Ugur Yuksel, investment manager at ABN AMRO Sustainable Impact Fund, commented: “The Protein Brewery has successfully translated strong scientific foundations into a robust industrial-scale production process and a growing commercial business, exactly the profile we look for in companies that can deliver measurable environmental impact at scale”.